Multivariate analyses focusing on the 7-year CIR
| Covariates . | RR . | 95% CI . | P value . |
|---|---|---|---|
| Only including significant covariates in univariate analysis | |||
| No. of PT-LU HLA shared mismatches against the WU | |||
| 0 or 1 | 1.00 | ||
| ≥2 | 0.23 | 0.07-0.75 | .015 |
| Year of transplant | |||
| <2012 | 1.00 | ||
| ≥2012 | 0.62 | 0.40-0.96 | .033 |
| Recipient body weight, kg | |||
| <70 | 1.00 | ||
| ≥70 | 0.65 | 0.43-0.99 | .045 |
| Primary disease | |||
| Acute leukemia | 1.00 | ||
| MDS | 0.31 | 0.10-0.98 | .046 |
| Conditioning regimen intensity | |||
| Reduced intensity | 1.00 | ||
| Myeloablative | 0.49 | 0.31-0.76 | .0016 |
| Addition of cytogenetics and grade 2-4 acute GVHD | |||
| No. of PT-LU HLA shared mismatches against the WU | |||
| 0 or 1 | 1.00 | ||
| ≥2 | 0.28 | 0.09-0.91 | .035 |
| Year of transplant | |||
| <2012 | 1.00 | ||
| ≥2012 | 0.54 | 0.33-0.87 | .013 |
| Recipient body weight, kg | |||
| <70 | 1.00 | ||
| ≥70 | 0.63 | 0.40-0.99 | .044 |
| Primary disease | |||
| Acute leukemia | 1.00 | ||
| MDS | 0.43 | 0.13-1.36 | .15 |
| Cytogenetics | |||
| Poor risk | 1.00 | ||
| Other risk | 1.07 | 0.67-1.71 | .77 |
| Conditioning regimen intensity | |||
| Reduced intensity | 1.00 | ||
| Myeloablative | 0.58 | 0.36-0.94 | .027 |
| Grade 2-4 acute GVHD | |||
| No | 1.00 | ||
| Yes | 0.51 | 0.31-0.83 | .007 |
| Addition of cytogenetics and chronic GVHD | |||
| No. of PT-LU HLA shared mismatches against the WU | |||
| 0 or 1 | 1.00 | ||
| ≥2 | 0.31 | 0.09-0.99 | .048 |
| Year of transplant | |||
| <2012 | 1.00 | ||
| ≥2012 | 0.40 | 0.24-0.67 | <.0005 |
| Recipient body weight, kg | |||
| <70 | 1.00 | ||
| ≥70 | 0.56 | 0.35-0.90 | .016 |
| Primary disease | |||
| Acute leukemia | 1.00 | ||
| MDS | 0.48 | 0.14-1.65 | .24 |
| Cytogenetics | |||
| Poor risk | 1.00 | ||
| Other risk | 1.08 | 0.67-1.75 | .75 |
| Conditioning regimen intensity | |||
| Reduced intensity | 1.00 | ||
| Myeloablative | 0.53 | 0.33-0.87 | .012 |
| Chronic GVHD | |||
| No | 1.00 | ||
| Yes | 0.50 | 0.32-0.80 | <.004 |
| Covariates . | RR . | 95% CI . | P value . |
|---|---|---|---|
| Only including significant covariates in univariate analysis | |||
| No. of PT-LU HLA shared mismatches against the WU | |||
| 0 or 1 | 1.00 | ||
| ≥2 | 0.23 | 0.07-0.75 | .015 |
| Year of transplant | |||
| <2012 | 1.00 | ||
| ≥2012 | 0.62 | 0.40-0.96 | .033 |
| Recipient body weight, kg | |||
| <70 | 1.00 | ||
| ≥70 | 0.65 | 0.43-0.99 | .045 |
| Primary disease | |||
| Acute leukemia | 1.00 | ||
| MDS | 0.31 | 0.10-0.98 | .046 |
| Conditioning regimen intensity | |||
| Reduced intensity | 1.00 | ||
| Myeloablative | 0.49 | 0.31-0.76 | .0016 |
| Addition of cytogenetics and grade 2-4 acute GVHD | |||
| No. of PT-LU HLA shared mismatches against the WU | |||
| 0 or 1 | 1.00 | ||
| ≥2 | 0.28 | 0.09-0.91 | .035 |
| Year of transplant | |||
| <2012 | 1.00 | ||
| ≥2012 | 0.54 | 0.33-0.87 | .013 |
| Recipient body weight, kg | |||
| <70 | 1.00 | ||
| ≥70 | 0.63 | 0.40-0.99 | .044 |
| Primary disease | |||
| Acute leukemia | 1.00 | ||
| MDS | 0.43 | 0.13-1.36 | .15 |
| Cytogenetics | |||
| Poor risk | 1.00 | ||
| Other risk | 1.07 | 0.67-1.71 | .77 |
| Conditioning regimen intensity | |||
| Reduced intensity | 1.00 | ||
| Myeloablative | 0.58 | 0.36-0.94 | .027 |
| Grade 2-4 acute GVHD | |||
| No | 1.00 | ||
| Yes | 0.51 | 0.31-0.83 | .007 |
| Addition of cytogenetics and chronic GVHD | |||
| No. of PT-LU HLA shared mismatches against the WU | |||
| 0 or 1 | 1.00 | ||
| ≥2 | 0.31 | 0.09-0.99 | .048 |
| Year of transplant | |||
| <2012 | 1.00 | ||
| ≥2012 | 0.40 | 0.24-0.67 | <.0005 |
| Recipient body weight, kg | |||
| <70 | 1.00 | ||
| ≥70 | 0.56 | 0.35-0.90 | .016 |
| Primary disease | |||
| Acute leukemia | 1.00 | ||
| MDS | 0.48 | 0.14-1.65 | .24 |
| Cytogenetics | |||
| Poor risk | 1.00 | ||
| Other risk | 1.08 | 0.67-1.75 | .75 |
| Conditioning regimen intensity | |||
| Reduced intensity | 1.00 | ||
| Myeloablative | 0.53 | 0.33-0.87 | .012 |
| Chronic GVHD | |||
| No | 1.00 | ||
| Yes | 0.50 | 0.32-0.80 | <.004 |